Nivolumab-induced keratitis and Vogt-Koyanagi-Harada syndrome–like eruptions: a case report
Keywords:
Keratitis, Melanoma, Nivolumab, Uveomeningoencephalitic syndromeAbstract
We report on a case of simultaneous kerato-uveitis and Vogt-Koyanagi-Harada syndrome–like eruptions associated with nivolumab treatment in a 44-year-old woman with metastatic rectal melanoma. Despite treatment for immune-related adverse events and discontinuation of nivolumab, the patient developed severe vertigo and tinnitus at week 7, as well as progressive depigmentation of her skin and hair and fundal hypopigmentation since month 2. Timely and adequate treatment is needed to improve clinical outcomes and reduce the risk of vision loss. Clinicians should raise their awareness of concurrent immune-related adverse events for any visual or neurological symptoms, especially when immune checkpoint inhibitors are used.
References
1. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol 2015;7:97-106.
2. Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol 2020;10:91.
3. Meng Q, Yang P, Li B, et al. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci 2006;47:4444-52.
4. Chen L, Pai V, Levinson R, et al. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocul Immunol Inflamm 2009;17:47-55.
5. Amadi-Obi A, Yu CR, Liu X, et at. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007;13:711-8.
6. Yoshida M, Kunikata H, Nakazawa T. Intraocular concentrations of cytokines and chemokines in a unique case of nivolumab-induced uveitis. Ocul Immunol Inflamm 2020;28:850-3.
7. Losonczy G, Gijs M, Nuijts RMMA. Nivolumab-induced ulcerative keratitis: a case report. Cornea 2021;40:656-8.
8. Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 2020;20:252.
9. Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol 2017;44:975-6.
10. Fujimura T, Kambayashi Y, Tanita K, et al. HLADRB1* 04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol
2018;45:735-7.
11. Nguyen AT, Elia M, Materin MA, Sznol M, Chow J. Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation. Cornea 2016;35:399-401.
12. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 2000;165:7323-9.
13. Wang W, Lam WC, Chen L. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother 2019;68:85-95.
14. Obata S, Saishin Y, Teramura K, Ohji M. Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 2019;10:67-74.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Hong Kong Journal of Ophthalmology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal has a fully Open Access policy and publishes all articles under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. For any use other than that permitted by this license, written permission must be obtained from the Journal.
